glp 1 for non obese Poll: in 8 Adults Say They Are Currently Taking a GLP-1 Drug Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford What is the pipeline for

Although CV outcomes trials with GLP-1RAs (LEADER and SUSTAIN-6) and SGLT2 inhibitors (EMPA-REG OUTCOME and CANVAS) showed significantly reduced occurrences of the pre-specified primary composite endpoint comprised of CV death, non-fatal myocardial infarction, and non-fatal stroke in T2D patients at high risk of CV events, the treatment effects on the individual components of the primary composite endpoint differed between drug classes, and even between different members of the same class [22, 23]

And sadly, this has been shown in more than one study

Importantly for GLP-1 therapy, which often requires urgent titration (weight-loss drugs have fastest impacts initially), quicker approvals can improve adherence: patients are less likely to abandon treatment if they get started immediately

They are generally manageable and typically improve over time